GlassScriptPhysician profile
Stephen P Dubin
NPI 1023311040
$1,738.20
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $437 · 2021: $387 · 2022: $463 · 2023: $182 · 2024: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.59 | 2021-2023 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $253.07 | 2019-2021 | |
| Novo Nordisk INC | $195.70 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Abiomed | $139.62 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $120.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $113.98 | 2020-2021 | |
| Eisai INC. | $101.75 | 2020-2021 | |
| Pfizer INC. | $93.46 | 2022-2023 | |
| Boston Scientific Corporation | $61.38 | 2019-2021 | |
| Glaxosmithkline, LLC. | $41.68 | 2020 | |
| Amgen INC. | $36.55 | 2019-2023 | Otezla, Repatha |
| Dexcom, INC. | $36.24 | 2021 | |
| Forte Bio-Pharma LLC | $35.63 | 2020-2021 | |
| Astellas Pharma US INC | $33.44 | 2023 | Veozah |
| Allergan, INC. | $26.06 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.65 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.89 | 2022 | |
| Arbor Pharmaceuticals, INC. | $20.04 | 2020 | |
| Aytu Biopharma, INC. | $19.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.72 | 2022 | |
| Amarin Pharma, INC. | $18.05 | 2022 | |
| Biodelivery Sciences International, INC. | $14.89 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.07 | 2022 | |
| Coala Life INC | $12.77 | 2021 | |
| Lilly USA, LLC | $12.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.